Search Results - Shakeel Modak

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival by Irene Y. Cheung, Brian H. Kushner, Shakeel Modak, Ellen M. Basu, Stephen S. Roberts, Nai-Kong V. Cheung

    Published in OncoImmunology (2017-11-01)
    Get full text
    Article


  2. 2

    Long Prime–Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer Vaccine by Irene Y. Cheung, Audrey Mauguen, Shakeel Modak, Ellen M. Basu, Yi Feng, Brian H. Kushner, Nai Kong Cheung

    Published in Vaccines (2024-05-01)
    Get full text
    Article


  3. 3

    Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS disease by Christina Fong, Brian H. Kushner, Angela Di Giannatale, Gunes Gundem, Shanita Li, Stephen S. Roberts, Ellen M. Basu, Anita Price, Nai-Kong V. Cheung, Shakeel Modak

    Published in Frontiers in Oncology (2023-01-01)
    Get full text
    Article


  4. 4

    Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells by Qin Liu, Archana Thakur, Lawrence G Lum, Dana Schalk, Anthony F Shields, Daniel W Lee, Nai-Kong V Cheung, Maxim Yankelevich, Shakeel Modak, Roland Chu, Jeffrey Taub, Alissa Martin, Amy Schienshang, Sarah Whitaker, Katie Rea

    Published in Journal for ImmunoTherapy of Cancer (2024-03-01)
    Get full text
    Article


  5. 5

    A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. by Oren J Becher, Nathan E Millard, Shakeel Modak, Brian H Kushner, Sofia Haque, Ivan Spasojevic, Tanya M Trippett, Stephen W Gilheeney, Yasmin Khakoo, David C Lyden, Kevin C De Braganca, Jill M Kolesar, Jason T Huse, Kim Kramer, Nai-Kong V Cheung, Ira J Dunkel

    Published in PLoS ONE (2017-01-01)
    Get full text
    Article


  6. 6

    Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies by Kim Kramer, Neeta Pandit-Taskar, Brian H. Kushner, Pat Zanzonico, John L. Humm, Ursula Tomlinson, Maria Donzelli, Suzanne L. Wolden, Sophia Haque, Ira Dunkel, Mark M. Souweidane, Jeffrey P. Greenfield, Satish Tickoo, Jason S. Lewis, Serge K. Lyashchenko, Jorge A. Carrasquillo, Bae Chu, Christopher Horan, Steven M. Larson, Nai-Kong V. Cheung, Shakeel Modak

    Published in Journal of Hematology & Oncology (2022-11-01)
    Get full text
    Article


Search Tools: